This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Masimo (MASI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Masimo (MASI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.
Masimo (MASI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 4.82% and 1.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.
ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ConforMIS (CFMS) delivered earnings and revenue surprises of 15.38% and 2.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.63% and 0.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Masimo (MASI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Masimo and Black Knight have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Masimo and Black Knight have been highlighted as Zacks Bull and Bear of the Day.
Bull of the Day: Masimo Corp. (MASI)
by Bryan Hayes
This stock has benefitted from a resurgence in the health care sector.
3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
Masimo's (MASI) New FDA Approval to Improve Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the FDA's clearance for the Rad-G with Temperature is expected to support clinicians in almost any care scenario.
Intuitive Surgical (ISRG) Gains Following Q1 Earnings Beat
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.
3 Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Masimo (MASI) and Ocuphire Pharma, Inc. (OCUP) have performed compared to their sector so far this year.
QuidelOrtho (QDEL) Reports Solid Preliminary Q1 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued strength in its non-respiratory product sales.
3 Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Intuitive Surgical (ISRG) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Here's Why You Should Hold Teladoc Health (TDOC) Stock Now
by Zacks Equity Research
Teladoc Health (TDOC) remains well-poised for growth on the back of solid revenues, sustained demand for virtual care services and sufficient cash-generating abilities.
Masimo (MASI) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Masimo's (MASI) slew of product launches.
BD's (BDX) New Launch to Result in Optimal IV Placement
by Zacks Equity Research
BD's (BDX) latest launch is expected to advance its vision of a One-Stick Hospital Stay by improving the first-stick success in IV placements.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) Established Pharmaceuticals Division (EPD) and Diabetes arm are boosting business in recent months.
Will Masimo (MASI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
PacBio's (PACB) New Offering to Enable High-Throughput Workflows
by Zacks Equity Research
PacBio's (PACB) latest launch is expected to combine the power of HiFi sequencing and Nanobind technology to optimize sample preparation workflows for its high-volume customers.